OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + Ribociclib
Phase 1Recruiting 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Cancer
Conditions
Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
Trial Timeline
Feb 26, 2024 → Aug 1, 2027
NCT ID
NCT06239467About OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + Ribociclib
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + Ribociclib is a phase 1 stage product being developed by OnKure Therapeutics for Advanced Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06239467. Target conditions include Advanced Cancer, Breast Cancer, Advanced Solid Tumors.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Cancer were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06239467 | Phase 1 | Recruiting |
Competing Products
20 competing products in Advanced Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-4359 | Moderna | Phase 2 | 0 |
| mRNA-4106 | Moderna | Phase 1 | 0 |
| AK-105 | Akeso | Phase 1 | 29 |
| AFM24 + Atezolizumab 840 MG in 14 ML Injection | Affimed | Phase 1/2 | 14 |
| EXS21546 | Biotrial | Phase 1/2 | 14 |
| SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent) | Syros Pharmaceuticals | Phase 1 | 11 |
| Necitumumab + Gemcitabine + Carboplatin | Eli Lilly | Phase 2 | 27 |
| Pemetrexed + Erlotinib + Pemetrexed + Erlotinib | Eli Lilly | Phase 2 | 35 |
| NBTXR3 | Nanobiotix | Phase 1/2 | 33 |
| pegfilgrastim + LY2523355 | Eli Lilly | Phase 1 | 29 |
| SON-1010 | Sonnet BioTherapeutics | Phase 1 | 27 |
| SON-1010 | Sonnet BioTherapeutics | Phase 1/2 | 18 |
| BT1718 | Bicycle Therapeutics | Phase 1/2 | 22 |
| Zentalis + Gemzar | Zentalis Pharmaceuticals | Phase 2 | 29 |
| IMC-18F1 | Eli Lilly | Phase 1 | 29 |
| Tadalafil + Gemcitabine | Eli Lilly | Phase 1 | 29 |
| OKI-179 | OnKure Therapeutics | Phase 1 | 19 |
| LY3499446 + Abemaciclib + Cetuximab + Erlotinib + Docetaxel | Eli Lilly | Phase 1/2 | 24 |
| LY3434172 | Eli Lilly | Phase 1 | 21 |
| ACR-2316 | Acrivon Therapeutics | Phase 1 | 26 |